Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
Guoxia JiQinghua GuoQidi XueRuifang KongShiben WangKang LeiRenmin LiuXuekun WangPublished in: Molecules (Basel, Switzerland) (2021)
GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood glucose. In this study, a series of novel GPR120 agonists were designed and synthesized to improve the stability and hydrophilicity of the phenylpropanoic acid GPR120 agonist TUG-891. Compound 11b showed excellent GPR120 agonistic activity and pharmacokinetic properties, and could reduce the blood glucose of normal mice in a dose-dependent manner. In addition, no hypoglycemic side effects were observed even at a dose of 100 mg/kg. Moreover, 11b showed good anti-hyperglycemic effects in diet-induced obese (DIO) mice. Molecular simulation illustrated that compound 11b could enter the active site of GPR120 and interact with ARG99. Taken together, the results indicate that compound 11b might be a promising drug candidate for the treatment of T2DM.
Keyphrases
- blood glucose
- type diabetes
- glycemic control
- fatty acid
- cardiovascular disease
- weight loss
- insulin resistance
- blood pressure
- emergency department
- induced apoptosis
- skeletal muscle
- bariatric surgery
- high fat diet induced
- cell proliferation
- signaling pathway
- cell cycle arrest
- endoplasmic reticulum stress
- drug induced
- obese patients
- replacement therapy